Skip to content

A MONOGRAPH ON SOUND AND THE BODY

Vibroacoustic Guide

An evidence-first introduction to the clinical use of low-frequency sound vibration, delivered through beds, chairs, mats, and handheld transducers tuned between 30 and 120 Hz.

What is vibroacoustic therapy

Vibroacoustic therapy, usually shortened to VAT, is a non-invasive modality that delivers low-frequency sound vibrations, typically between 30–120 Hz, directly into the body through transducers embedded in a bed, chair, mat, or handheld device. The sound is almost always sinusoidal, and it is often paired with therapeutic music so that the patient hears the music above the audible range and feels the low frequencies through bone, tissue, and the sensory nervous system at once (Bartel & Mosabbir, 2021; Kantor et al., 2022).

In practice, a session lasts between twenty and forty-five minutes. The patient lies down or reclines. The device plays a tone, or a composition built on tones, at a chosen therapeutic frequency. The most commonly studied and recommended frequency is 40 Hz, especially for pain, Parkinson's motor symptoms, and cognitive work in older adults (Bae et al., 2025; Mosabbir et al., 2020).

VAT sits at the intersection of music therapy, physical medicine, and integrative neurology. It is studied. It is taught. It has a small but real research base. It is also easy to dismiss at a glance, and part of the purpose of this site is to give the evidence the careful reading it deserves.

Olav Skille and the Nordic pioneers

Vibroacoustic therapy was developed in the late 1970s by Olav Skille, a Norwegian educator and music therapist working with children who had severe motor and sensory impairments. Skille observed that certain children responded to low-frequency musical vibration in ways they did not respond to conventional sound or touch. He began building experimental devices, Styrofoam mattresses wired with loudspeakers, then purpose-built beds and chairs, and testing specific low frequencies for specific clinical effects.

Skille's original company, TheSoundWell, seeded what is now a small international field. His early collaborators and successors include the Finnish vibroacoustic pioneer Petri Lehikoinen, who helped establish the VIBRAC Skille-Lehikoinen Centre for Vibroacoustic Therapy and Research, and a generation of music therapy researchers in Finland and Estonia (Campbell, Hynynen, Burger, & Ala-Ruona, 2019; Rüütel, Vinkel, & Eelmäe, 2017).

The Nordic lineage matters. Most of the serious clinical research on VAT over the past four decades has come out of Scandinavia and the Baltics. Newer work is coming from Canada (Bartel, Mosabbir, and collaborators at the University of Toronto), Kazakhstan (Konkayev and collaborators, on respiratory applications), Korea (Bae and colleagues, on cognitive effects in older adults), and a handful of U.S. and Australian investigators (Bartel, Chen, Alain, & Ross, 2017; Konkayev & Bekniyazova, 2023; Bae et al., 2025).

The field is small. The references on this site are most of what has been published in English. A reader who works through them has, in a real sense, read the literature.

Late 1970s Skille in Norway 1980s TheSoundWell founded 1990s Lehikoinen & VIBRAC in Finland 2000s North American clinical research begins 2010s Music and Medicine journal as hub 2020s Global expansion

Low-frequency sine waves, explained simply

A sine wave is the simplest possible pure tone. It has one frequency, one amplitude, and no harmonics. When a 40 Hz sine wave is sent through a transducer pressed against the body, the body physically oscillates forty times per second at that location. The vibration travels through skin, fat, muscle, fascia, bone, and fluid, and it engages specific sensory receptors, primarily the Pacinian corpuscles, which are tuned to vibration in roughly this frequency range (Bartel & Mosabbir, 2021).

The proposed mechanisms of action include:

  • Activation of muscle spindles and Golgi tendon organs, modulating spinal reflexes and reducing muscle tone (Zeng et al., 2023; Avvantaggiato et al., 2020)
  • Neural entrainment at 40 Hz of gamma-band oscillations associated with attention, memory, and sensory integration (Bartel et al., 2017; Bae et al., 2025)
  • Parasympathetic activation and stress reduction through vagal afferent stimulation (Bartel & Mosabbir, 2021)
  • Analgesic effects via the spinal gate-control pathway (Casale & Hansson, 2022)
  • Improved local blood and lymphatic circulation

None of these mechanisms is fully established. All of them have supporting work. The Research page covers what is known and what is still in question.

amplitude wavelength 40 Hz 40 cycles / second

How the therapy is delivered

Bed

Full-length vibroacoustic beds have multiple embedded transducers spaced along the length of the spine. They are used for whole-body sessions and are the most common form factor in clinical VAT research. Session length: typically 20–30 min.

Chair or Lounger

Recliners and physioacoustic chairs concentrate vibration along the back, seat, and head. They are used in outpatient clinics, dental and oncology settings, and consumer wellness spaces. Session length: typically 20–30 min.

Mat

Portable vibroacoustic mats are a lower-cost, mobile option and are frequently used in schools, therapy offices, and private homes. They are generally lighter amplitude than beds. Session length: typically 15–30 min.

Handheld Transducer

Localized handheld or wearable transducers are used for focal vibration on a specific muscle or joint. This overlaps with what the rehabilitation literature calls "focal muscle vibration" (fMV) and is studied for post-stroke spasticity and motor recovery (Giorgi, Donati, Platano, & Tedeschi, 2024; Toscano et al., 2020).

If you have a pacemaker, ICD, cochlear implant, deep brain stimulator, vagus nerve stimulator, or spinal cord stimulator… do not receive vibroacoustic therapy without explicit clearance from the device manufacturer and your treating physician. See Safety and Contraindications for more.